top of page
Scientist Using Microscope

About Us

Accelerating drug discovery through Molecular Fingerprint™ Platform

Our Vision

Ibis is defining the future of precision by guiding drugs toward beneficial on-targets and away from harmful off-targets. Its AI-driven Molecular Fingerprint™  Platform engine enables valuable insights into information about drug candidates with the potential for maximum efficacy and safety. Transcending the one disease-one target-one drug paradigm allows the Ibis platform to integrate polypharmacology, selectivity profiling, safety assessments, and drug repurposing into a coherent framework applicable to all stages of drug discovery and development. 

Meet Our Team

Scientist on Computer writing
sam shrivastava executive chaiman, founder, and CEO biotech entrepreneur ASHA therapeutics, venn therapeutics, CBMG cellular biomedicine group harvard medical school office of online learning external education
sam shrivastava excutive chairman, founder, and CEO at IBIS therapeutics biotech entrepreneur
wayne guida phd president and chief scientific officer computational drug discovery novatis, NAI, schrodinger
wayne guida phd president and chief scientific officer computational drug discovery at IBIS therapeutics
william glauser PHD MBA chief strategic officer computational drug discovery at IBIS therapeutics 101 partners xtalpi schrodinger
william a glauser phd mba chief stratefic officer computational drug discovery at IBIS therapeutics
EDITED JULIA 1.png
julia 2.png
abby garcia los angeles head of people and culture at IBIS therapeuticsc , salinger ventures
abby garcia los angeles head of people and culture at IBIS therapeuticsc , salinger ventures
bottom of page